Adam Throup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam Throup has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Helleday
Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
4 shared publications - Pål Stenmark
Stockholm University
3 shared publications Azita Rasti
Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
2 shared publicationsGiorgia Benzi
Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
2 shared publicationsHannah Stigsdotter
Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
2 shared publicationsIngrid Almlöf
Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
2 shared publications
Latest Publications
- Open Access
- 6 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM
Cellular target engagement technologies enable quantification of intracellular drug binding; however, simultaneous assessment of drug-associated phenotypes has proven challenging. Here, we present cellular target engagement by accumulation of mutant as a platform that can concomitantly evaluate drug-target interactions and phenotypic responses using conditionally stabilized drug biosensors. We observe that drug-responsive proteotypes are prevalent among reported mutants of known drug targets. Compatible mutants appear to follow structural and biophysical logic that permits intra-protein and paralogous expansion of the biosensor pool. We then apply our method to uncouple target engagement from divergent cellular activities of MutT homolog 1 (MTH1) inhibitors, dissect Nudix hydrolase 15 (NUDT15)-associated thiopurine metabolism with the R139C pharmacogenetic variant, and profile the dynamics of poly(ADP-ribose) polymerase 1/2 (PARP1/2) binding and DNA trapping by PARP inhibitors (PARPi). Further, PARP1-derived biosensors facilitated high-throughput screening for PARP1 binders, as well as multimodal ex vivo analysis and non-invasive tracking of PARPi binding in live animals. This approach can facilitate holistic assessment of drug-target engagement by bridging drug binding events and their biological consequences.
- 6 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Open AccessCoupling cellular drug-target engagement to downstream pharmacology with CeTEAM
Cellular target engagement technologies enable quantification of intracellular drug binding; however, simultaneous assessment of drug-associated phenotypes has proven challenging. Here, we present cellular target engagement by accumulation of mutant as a platform that can concomitantly evaluate drug-target interactions and phenotypic responses using conditionally stabilized drug biosensors. We observe that drug-responsive proteotypes are prevalent among reported mutants of known drug targets. Compatible mutants appear to follow structural and biophysical logic that permits intra-protein and paralogous expansion of the biosensor pool. We then apply our method to uncouple target engagement from divergent cellular activities of MutT homolog 1 (MTH1) inhibitors, dissect Nudix hydrolase 15 (NUDT15)-associated thiopurine metabolism with the R139C pharmacogenetic variant, and profile the dynamics of poly(ADP-ribose) polymerase 1/2 (PARP1/2) binding and DNA trapping by PARP inhibitors (PARPi). Further, PARP1-derived biosensors facilitated high-throughput screening for PARP1 binders, as well as multimodal ex vivo analysis and non-invasive tracking of PARPi binding in live animals. This approach can facilitate holistic assessment of drug-target engagement by bridging drug binding events and their biological consequences.
- Open Access
Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM
Cellular target engagement technologies are reforming drug discovery by enabling quantification of intracellular drug binding; however, simultaneous assessment of drug-associated phenotypes has proven challenging. CeTEAM ( ce llular target e ngagement by a ccumulation of m utant) is a platform that can concomitantly evaluate drug-target interactions and phenotypic responses for holistic assessment of drug pharmacology using conditionally-stabilized drug biosensors. We observe that drug-responsive proteotypes are prevalent among reported mutants of known drug targets. CeTEAM-compatible mutants follow structural and biophysical logic that permits intra-protein and paralogous expansion of the biosensor pool, as exemplified by alanine scanning of leucines within the PARP1 helical domain and transfer of PARP1 destabilization to the analogous PARP2 residue. We then apply CeTEAM to uncouple target engagement from divergent cellular activities of MTH1 inhibitors, dissect NUDT15-associated thiopurine metabolism with the R139C pharmacogenetic variant, and profile the live-cell dynamics of PARP1/2 binding and DNA trapping by PARP inhibitors. Further, PARP1-derived biosensors facilitated high-throughput screening of drug-like libraries for PARP1 binders, as well as multimodal ex vivo analysis and non-invasive tracking of PARPi binding in live animals. Our data suggests that CeTEAM can facilitate real-time, comprehensive characterization of target engagement by bridging drug binding events and their biological consequences.
Open AccessCoupling cellular drug-target engagement to downstream pharmacology with CeTEAM
Cellular target engagement technologies are reforming drug discovery by enabling quantification of intracellular drug binding; however, simultaneous assessment of drug-associated phenotypes has proven challenging. CeTEAM ( ce llular target e ngagement by a ccumulation of m utant) is a platform that can concomitantly evaluate drug-target interactions and phenotypic responses for holistic assessment of drug pharmacology using conditionally-stabilized drug biosensors. We observe that drug-responsive proteotypes are prevalent among reported mutants of known drug targets. CeTEAM-compatible mutants follow structural and biophysical logic that permits intra-protein and paralogous expansion of the biosensor pool, as exemplified by alanine scanning of leucines within the PARP1 helical domain and transfer of PARP1 destabilization to the analogous PARP2 residue. We then apply CeTEAM to uncouple target engagement from divergent cellular activities of MTH1 inhibitors, dissect NUDT15-associated thiopurine metabolism with the R139C pharmacogenetic variant, and profile the live-cell dynamics of PARP1/2 binding and DNA trapping by PARP inhibitors. Further, PARP1-derived biosensors facilitated high-throughput screening of drug-like libraries for PARP1 binders, as well as multimodal ex vivo analysis and non-invasive tracking of PARPi binding in live animals. Our data suggests that CeTEAM can facilitate real-time, comprehensive characterization of target engagement by bridging drug binding events and their biological consequences.
- 11 September 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (37) , 7758-7764
Novel spirocyclic systems via multicomponent aza-Diels–Alder reaction
Here we present a two-step diastereoselective methodology building on a multicomponent aza-Diels–Alder reaction.
- 11 September 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (37) , 7758-7764
Novel spirocyclic systems via multicomponent aza-Diels–Alder reaction
Here we present a two-step diastereoselective methodology building on a multicomponent aza-Diels–Alder reaction.
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (16) , 3897-3904
Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: Triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (16) , 3897-3904
Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: Triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines
- Open Access
- 20 September 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (40) , 9554-9559
Intramolecular thermal stepwise [2 + 2] cycloadditions: investigation of a stereoselective synthesis of [n.2.0]-bicyclolactones
A new method for the synthesis of highly functionalised cyclobutenes.
- 20 September 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (40) , 9554-9559
Open AccessIntramolecular thermal stepwise [2 + 2] cycloadditions: investigation of a stereoselective synthesis of [n.2.0]-bicyclolactones
A new method for the synthesis of highly functionalised cyclobutenes.